Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Mizue Terai"'
Development and optimization of orthotopic liver metastasis xenograft mouse models in uveal melanoma
Autor:
Bao Quoc Lam, Takahito Sugase, Meggie Danielson, Mizue Terai, Andrew E. Aplin, Takami Sato, J. Silvio Gutkind
Publikováno v:
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-14 (2020)
Journal of Translational Medicine
Journal of Translational Medicine
Background Patients with metastatic uveal melanoma (MUM) in the liver usually die within 1 year. The development of new treatments for MUM has been limited by the lack of diverse MUM cell lines and appropriate animal models. We previously reported th
A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis
Autor:
Misung Yi, Inna Chervoneva, David J. Eschelman, Takami Sato, P. Rani Anne, Carin F. Gonsalves, Robert D. Adamo, Marlana Orloff, Anthony N. Hage, Mizue Terai
Publikováno v:
Radiology
BACKGROUND: Overall survival (OS) for patients with uveal melanoma (UM) hepatic metastases is extremely poor. Therefore, stabilization of hepatic metastases is essential to prolonging OS. PURPOSE: To assess the safety and effectiveness of radioemboli
Publikováno v:
Current Protocols. 1
The propensity of uveal melanoma to metastasize to the liver hinders the accrual of micro-metastatic and end-stage disease tissue samples and restricts the investigation of metastatic uveal melanoma (MUM). Pre-clinical experimental animal models of M
Autor:
Andrew E. Aplin, Hanyin Cheng, Mizue Terai, Takami Sato, Masahiro Ohara, Ken Kageyama, Kengo Saito
Publikováno v:
Cancers, Vol 13, Iss 1104, p 1104 (2021)
Cancers
Volume 13
Issue 5
Cancers
Volume 13
Issue 5
Uveal melanoma (UM) is the most common cancer of the eye in adults. Up to 50% of UM patients subsequently develop metastases, especially in the liver. It has been reported that the retinoblastoma (RB) pathway is deregulated in more than 90% of UM des
Autor:
Lihong Zhang, Mizue Terai, Eduardo F. Farias, Julio A. Aguirre-Ghiso, Clinita E. Randolph, Naiming Zhou, Takami Sato, Timothy J. Purwin, Philip B. Wedegaertner, Andrew E. Aplin, Gregory G. Tall, Shihua Wu, Dougan McGrath, Thomas H. Charpentier, Dominic Lapadula, Jeffrey L. Benovic
Publikováno v:
Molecular Cancer Research. 17:963-973
Uveal melanoma is the most common intraocular tumor in adults and often metastasizes to the liver, leaving patients with few options. Recurrent activating mutations in the G proteins, Gαq and Gα11, are observed in approximately 93% of all uveal mel
Autor:
Mital Shah, Takami Sato, Bharat Awsare, Rajiv A. Kabadi, Mizue Terai, Gautam George, Gregary D. Marhefka
Publikováno v:
Tex Heart Inst J
Locoregional cytokine treatment, or immunoembolization, is an experimental targeted therapy for uveal melanoma metastatic to the liver. Unlike systemic cytokine treatments that have been associated with substantial toxicity, this method of drug deliv
Autor:
Bao Lam, Eric Londin, Takami Sato, Emma O. Link, Ankit K. Rochani, Gagan Kaushal, Alok Bhushan, Mizue Terai, Marlana Orloff
Publikováno v:
Cancers
Volume 12
Issue 2
Cancers, Vol 12, Iss 2, p 405 (2020)
Volume 12
Issue 2
Cancers, Vol 12, Iss 2, p 405 (2020)
Uveal melanoma (UM) is the most common primary eye malignancy in adults and up to 50% of patients subsequently develop systemic metastasis. Metastatic uveal melanoma (MUM) is highly resistant to immunotherapy. One of the mechanisms for resistance wou
Publikováno v:
Cancers
Cancers, Vol 13, Iss 5457, p 5457 (2021)
Cancers, Vol 13, Iss 5457, p 5457 (2021)
Simple Summary Hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) signaling plays an important role in the metastatic formation and therapeutic resistance to uveal melanoma. Here, we review the various functions of MET sign
Autor:
J. Silvio Gutkind, Takami Sato, Erin Sharpe-Mills, Andrew E. Aplin, Mizue Terai, Haley Klose, Rino S. Seedor, Marlana Orloff, Michael J. Mastrangelo
Publikováno v:
Journal of Clinical Oncology. 39:TPS9588-TPS9588
TPS9588 Background: Despite successful treatment of primary uveal melanomas (UM), up to 50% of patients subsequently develop systemic metastasis, with the liver involved in up to 90% of patients. Currently there is no US FDA-approved treatment for me
Autor:
Mizue Terai, Paolo Fortina, Shinji Ozaki, Ken Kageyama, Andrew E. Aplin, Takami Sato, Kengo Saito, Masahiro Ohara, Michael J. Mastrangelo
Publikováno v:
Journal of Translational Medicine, Vol 15, Iss 1, Pp 1-19 (2017)
Journal of Translational Medicine
Journal of Translational Medicine
Background Metastatic uveal melanoma is a highly fatal disease; most patients die from their hepatic metastasis within 1 year. A major drawback in the development of new treatments for metastatic uveal melanoma is the difficulty in obtaining appropri